About 454 Life Sciences
454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative GS Junior and GS FLX Systems for high-throughput DNA sequencing. Specific applications include de novo sequencing and resequencing of whole genomes, targeted resequencing of genomic regions of interest, metagenomics, transcriptome sequencing and methylation analysis. The hallmark of 454 Sequencing Systems are the long, highly accurate sequence reads, including paired end reads. The technology has enabled over 1,000 peer-reviewed publications in diverse research fields such as cancer, infectious disease, immunogenetics, drug discovery, agriculture, environmental ecology, paleontology and many more.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.